Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality.
CFTR
Cystic fibrosis
Gene therapy
Niosomes
Non-viral
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Oct 2020
15 Oct 2020
Historique:
received:
21
04
2020
revised:
27
07
2020
accepted:
07
08
2020
pubmed:
14
8
2020
medline:
22
5
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option for the treatment of cystic fibrosis (CF), being liposomes the most commonly used gene carriers. Niosomes offer a powerful alternative to liposomes due to their higher stability and lower cytotoxicity, provided by their non-ionic surfactant and helper components. In this work, a three-formulation screening is performed, in terms of physicochemical and biological behavior, in CF patient derived airway epithelial cells. The most efficient niosome formulation reaches 28% of EGFP expressing live cells and follows caveolae-mediated endocytosis. Transfection with therapeutic cystic fibrosis transmembrane conductance regulator (CFTR) gene results in 5-fold increase of CFTR protein expression in transfected versus non-transfected cells, which leads to 1.5-fold increment of the chloride channel functionality. These findings highlight the relevance of niosome-based systems as an encouraging non-viral gene therapy platform with potential therapeutic benefits for CF.
Identifiants
pubmed: 32791297
pii: S0378-5173(20)30741-9
doi: 10.1016/j.ijpharm.2020.119757
pii:
doi:
Substances chimiques
Chloride Channels
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119757Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.